This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital sold 2,957,386 shares of Viridian Therapeutics in Q4, an estimated $81.11 million based on quarterly average pricing. The sale is a sizable institutional reduction that could exert modest near-term selling pressure on the stock, but the report provides no company-specific catalyst or commentary.

Analysis

Kynam Capital sold 2,957,386 shares of Viridian Therapeutics in Q4, an estimated $81.11 million based on quarterly average pricing. The sale is a sizable institutional reduction that could exert modest near-term selling pressure on the stock, but the report provides no company-specific catalyst or commentary.